申请人:VIROVAX LLC
公开号:US20210238210A1
公开(公告)日:2021-08-05
A compound can include the structure of Formula 1, derivative thereof, prodrug thereof, salt thereof, stereoisomer thereof, tautomer thereof, polymorph thereof, or solvate thereof, or having any chirality at any chiral center:
R
1
includes a hydrogen or a substituent; R
2
includes a hydroxyl, hydroxyl-forming prodrug, or hydroxyl-leaving chemical moiety; R
3
includes a halogen; and R
4
includes a heterocycle. The compound can be an antiviral compound used in antiviral therapies.
一个化合物可以包含公式1的结构、其衍生物、前药、盐、立体异构体、互变异构体、多晶型或溶剂化物,或者在任何手性中心具有任何手性:R1包括氢或取代基;R2包括羟基、形成羟基的前药或离开羟基的化学基团;R3包括卤素;R4包括杂环。该化合物可以是一种用于抗病毒治疗的抗病毒化合物。